“…In addition, inactivation of AP-2 in primary cutaneous melanoma cells (AP-2 positive) by means of a dominant-negative AP-2 gene (AP-2B) led to deregulation of the metalloproteinase MMP-2 gene and increased the cells tumor and metastatic potential in nude mice (Gershenwald et al, 2001). Furthermore, functional AP-2-binding elements have been identified in other genes involved in the progression of human melanoma such as p21/WAF1 (Zeng et al, 1997), intercellular adhesion molecule (I-CAM) (Grether-Beck et al, 1996), c-erbB-2/HER-2/neu (Hollywood and Hurst, 1993;Bosher et al, 1995;Turner et al, 1998), plasminogen activator inhibitor type I (PAI-1) (Descheemaeker et al, 1992), insulin-like growth factor binding protein-5 (Duan and Clemmons, 1995), transforming growth factor-alpha (TGF-a) (Wang et al, 1997), vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) (Gille et al, 1997(Gille et al, , 2000, E-cadherin (Batsche et al, 1998), hepatocyte growth factor (HGF) , and c-Myc (Gaubatz et al, 1995). Loss of AP-2 was also observed in clinical specimens of advanced primary and metastatic melanoma, which was associated with malignant transformation and elevated risk of tumor progression (Karjalainen et al, 1998;Baldi et al, 2001), thus supporting the hypothesis that loss of AP-2 is a crucial event in the progression and metastasis of melanoma.…”